Showing results (331-340 of 658) with videos related to
Sort By:
Pageof 66
Plos One|May 16, 2014
Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse modelHong Jiang, Karen Clise-Dwyer, Kathryn E Ruisaard, et al.Neoplasia (New York, N.Y.)|June 23, 2006
Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growthOk-Hee Lee, Juan Fueyo, Jing Xu, et al.Journal of Neuro-Oncology|September 11, 2015
Primary and secondary gliosarcomas: clinical, molecular and survival characteristicsDavid Cachia, Carlos Kamiya-Matsuoka, Jacob J Mandel, et al.Cancers|July 26, 2020
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against GlioblastomaEmeline Tabouret, Herui Wang, Niranjana Amin, et al.Neuro-Oncology|March 29, 2018
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686Jerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.Neuro-Oncology|June 22, 2013
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyJerrold L Boxerman, Zheng Zhang, Yair Safriel, et al.Journal of Neuro-Oncology|July 25, 2020
Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor SectionJohn Lynes, Alvina A Acquaye, Hannah Sur, et al.Cancers|October 16, 2025
Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935Emeline Tabouret, Herui Wang, Niranjana Amin, et al.Biorxiv : the Preprint Server for Biology|June 11, 2025
Single Cell Spatial Profiling Identifies Region-Specific Extracellular Matrix Adhesion and Signaling Networks in GlioblastomaArpan De, Santiago A Forero, Ali Pirani, et al.Neurosurgery|December 20, 2007
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety resultsMichael A Vogelbaum, John H Sampson, Sandeep Kunwar, et al.Pageof 66